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Introduction
There are many indications for term labor induction,
including postdate pregnancy, preeclampsia, diabetes
mellitus, oligohydramnios, intrauterine fetal growth
retardation and abnormal antepartum fetal surveil-
lance results [1]. With more than 15% of all gravid
women requiring aid in cervical ripening and labor
induction, there is widespread interest in, and demand
for, an effective and safe method of assistance. The
immature cervix is the greatest barrier to labor induc-
tion. As oxytocin affects only uterine contractions and
not cervical ripening, prostaglandin agents are the first
choice for labor inductions as they exert a local effect
on the cervix, causing effacement and dilatation, and
stimulate myometrial contraction, increasing the likeli-
hood of success. Dinoprostone has been the agent of
choice for preinduction cervical ripening for several
decades and it is currently one of the pharmacologic
agents approved by the United States’ Food and Drug
Administration (FDA) for this purpose. Although widely
used, it has two disadvantages: it is expensive and it
requires continuous refrigeration. Thus, there is a need
for less costly and less temperature-sensitive alterna-
tives. A proposed alternative is misoprostol, a synthetic
prostaglandin E1 analog. Misoprostol, initially used to
treat peptic ulcers caused by prostaglandin synthetase
inhibitors, was approved by the FDA for obstetric use
in April 2002.
Since the 1992 letter of Margulies et al, published
in the Lancet [2], and the initial American clinical report
by Sanchez-Ramos et al, detailing the use of misopros-
tol for cervical ripening and labor induction [3], there
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has been growing interest in this agent [4–6]. The pre-
ferred dosage is 100 μg orally or 25 μg vaginally every 4
hours. However, excessive uterine contractility resulting
in fetal distress is a cause for concern [7–15]. Comparing
the oral and vaginal administrations of misoprostol, oral
administration is easier and has greater acceptability
among women. Further, absorption is more rapid and
possibly more predictable, with a peak serum concen-
tration following oral administration of 34 minutes
and a half-life of 20–40 minutes. Peak serum concen-
tration for vaginal administration is 60–80 minutes,
this level being sustained for up to 4 hours [16].
Although the direct local effect of vaginal administra-
tion on cervical ripening may be advantageous [17],
the shorter half-life of oral delivery may be beneficial 
in the event of uterine hyperstimulation. In order to
avoid uterine hyperstimulation, it appears reasonable
to suggest that oral misoprostol should be adminis-
tered in small, frequent doses, titrated against the
uterine response [18,19]. The aim of this study was to
evaluate the safety and efficacy of titrated oral miso-
prostol for labor induction.
Materials and Methods
This study was conducted between July 2002 and June
2005. The sample population comprised 77 pregnant
women (37 nullipara and 40 multipara) with live sin-
gleton, cephalic presentations requiring labor induc-
tion after 37 weeks of gestation due to medical,
obstetric or psychosocial indications. Exclusion crite-
ria were: parity over five; previous cesarean section;
more favorable cervix (Bishop’s score ≥ 7). Since the
length of active labor differs between nulliparous and
multiparous women [20,21], the sample population
was subgrouped in order to analyze the outcomes of
labor induction. Although misoprostol is manufactured
as oral tablets, it is water soluble. The uterine activity
produced by an oral solution is faster and stronger 
than that of an oral tablet, or via the rectal or vaginal 
route [22]. To overcome the inaccuracy inherent in
manual division of the misoprostol tablet, one tablet
(200 μg) was dissolved in 200 mL of water in a medi-
cine bottle by the on-duty nurse. The bottle was shaken
well before each administration [18]. The 1μg/mL miso-
prostol solution facilitated accurate control of titrated
oral dosage. Labor was induced with the 1 μg/mL
solution according to the principles of titrated oral
dosing [19], the basic general principles of which are
as follows:
1. One tablet (200 μg) of misoprostol is dissolved in
200 mL of water (1 μg/mL of water).
2. The maximum cumulative dosage of misoprostol is
1,600 μg.
3. Initial administration of 20 μg/hour is undertaken
until adequate uterine contractions are achieved. If
contractions do not occur after four of the above
doses, the dosage is increased to 40 μg and repeated
every hour until uterine contractions are achieved,
with a maximum of four more doses. If response
still remains poor after 8 hours, the dosage should
be increased to 60 μg/hour until adequate contrac-
tions occur.
4. Once uterine activity is deemed adequate, no further
misoprostol is given.
5. If contractions subsequently become inadequate,
hourly doses of misoprostol solution are started at
10 μg and may be increased to 20 μg and perhaps
40 μg, based on uterine responsiveness. This is re-
peated until adequate uterine contractions occur.
6. Fetal heart rate and uterine activity are continuously
monitored throughout labor induction.
7. Induction failure is defined as not entering into 
the active phase after 36 hours using misoprostol
solution with a maximum cumulative dosage of
1,600 μg.
8. Intravenous magnesium sulfate (4 g over 30 minutes)
may be given if uterine hyperstimulation occurs.
If rupture of the membranes has not occurred despite
a Bishop’s score of 9 or above, artificial rupture of 
the membranes may be performed. Supplemental oxy-
tocin may be used when uterine contractions are inade-
quate when entering the active phase because of poor
response to misoprostol. Cesarean section is performed
after induction failure or a prolonged active phase.
Adequate uterine contractions are defined as con-
tractions that occur every 2–3 minutes and last 60–90
seconds with an intrauterine pressure of 50–60 mmHg.
Tachysystole is defined as the presence of at least six
contractions in 10 minutes over at least two 10-minute
windows. Hyperstimulation is defined as prolonged
uterine contractions (each contraction lasting at least
2 minutes) or tachysystole that result in fetal heart
deceleration requiring intervention, either by tocolytics
or by delivery.
Our main outcome measurements were the number
of women who delivered infants vaginally within 12,
24 and 36 hours of induction. Other efficacy measure-
ments included the interval from induction to vaginal
delivery and active phase, total dosage of misoprostol,
number of women given oxytocin and the number of
induction failures. The number of cesarean deliveries,
uterine tachysystole, hyperstimulation rates and occur-
rence of side effects were also recorded, as were neonatal
outcomes including low Apgar score (< 7 at 5 minutes)
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and neonatal unit admission. The entry characteristics
of the patients, including age, height, weight, parity,
gestational age at induction, indication for induction
and cervical score before the start of induction, were
also recorded.
Results
Seventy-seven pregnant women (37 nullipara and 40
multipara) were enrolled in this study. Demographic
characteristics and indications for induction are presen-
ted in Tables 1 and 2, respectively. Seventy-five women
experienced active labor within 24 hours (97.4%; 35
nullipara and 40 multipara), and 72 completed vagi-
nal delivery within 24 hours (93.5%; 32 nullipara and
40 multipara). Seventy-four women completed vaginal
delivery within 36 hours (96.1%; 34 nullipara and 40
multipara), with three (three nullipara) delivering by ces-
arean section due to a prolonged active phase. Eight
women (10.4%) required oxytocin augmentation due
to poor response to misoprostol when entering the
active phase. Except for the seven patients (9.1%) who
experienced uterine tachysystole, there was no uterine
hyperstimulation or induction failure (Table 3).
The mean Bishop’s score for both nullipara and
multipara subgroups was 4. The mean interval from
induction to vaginal delivery for all the women was 9.7
hours, with a 2.3-hour active phase. The mean induc-
tion intervals for the nullipara and multipara subgroups
were 12.2 hours with a 3.0-hour active phase and  7.6
hours with a 1.7-hour active phase, respectively. The
mean dosage for the entire sample was 206 μg, while
for the nullipara and multipara subgroups was 228 μg
and 185 μg, respectively (Table 4).
Common side effects included nausea (11.7%) and
vomiting (10.4%); rare side effects were diarrhea (2.6%)
and shivering (1.3%). No pyrexia was seen. The median
birth weight of the newborns was 3,050 g (range, 2,100–
4,200 g) and neonatal outcomes were all good as no
infant had a low Apgar score (< 7 at 5 minutes) requir-
ing admittance to the neonatal unit.
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Table 1. Demographic characteristics of 77 patients (37 
nulliparas, 40 multiparas)
Characteristic Median Range
Age (yr) 26.8 17.9–45.4
Height (cm) 158.0 144–172
Weight (kg) 65.0 49.0–102.0
Gestation (wk) 39.1 36.3–42.1
Table 2. Indications for labor induction
Indication n (%)
Post-term 5 (6.5)
Hypertension 6 (7.8)
IUGR 3 (3.9)
PROM 15 (19.5)
Psychosocial 8 (10.4)
GDM 2 (2.6)
Other 38 (49.4)
IUGR = intrauterine growth retardation; PROM = premature rupture of mem-
brane; GDM = gestational diabetes mellitus.
Table 3. Outcomes of labor induction
Outcome Nullipara (n = 37) Multipara (n = 40) Total (n = 77) %
Active labor within
12 hr 27 37 64 83.1
24 hr 35 40 75 97.4
36 hr 37 40 77 100.0
Vaginal delivery within
12 hr 21 36 57 74.0
24 hr 32 40 72 93.5
36 hr 34 40 74 96.1
Augmentation with oxytocin 4 4 8 10.4
Cesarean section 3 0 3 3.9
Uterine tachysystole 4 3 7 9.1
Uterine hyperstimulation 0 0 0 0.0
Induction failure 0 0 0 0.0
Fetal distress 0 0 0 0.0
Discussion
Given the pharmacokinetics of misoprostol [16] and
the extreme inter- and intraindividual variation in terms
of uterine sensitivity, regular administration of oral miso-
prostol every 4 hours is not safe at high doses (≥ 100 μg)
[11]. In order to avoid uterine hyperstimulation and to
shorten the interval from induction to vaginal delivery,
we adopted the principle that misoprostol should be
administered orally in small, frequent doses (one dose
per hour generally), titrated against uterine response
and analogous to the conventional titrated use of oxy-
tocin. The 1-hour interval of oral administration was
developed according to the mathematical model of
the time to peak serum concentration (Tmax) and half-
life (T1/2) of oral misoprostol after absorption, which
virtually maintains a steady serum level of misoprostol
acid without large fluctuations, and increases by one
and one-third the peak serum concentration (Cmax) of
20 μg absorptive misoprostol every 4 hours [19]. This
method is easier to administer than vaginal supposito-
ries and is less expensive than intravenous oxytocin
given via an adjusting pump machine.
Parameters evaluated for safety were uterine tachy-
systole rate, uterine hyperstimulation rate, neonatal
outcome with low Apgar score and neonatal unit
admission. All these were satisfactory except tachysys-
tole, which occurred in seven patients (9.1%). When
tachysystole was found, the oral intake of misoprostol
solution was halted until uterine contractions became
inadequate and there was no uterine hyperstimulation.
The common side effects of nausea and vomiting were
not higher than other studies of high oral doses [15].
Clearly, small dosage incrementation, with continuous
adjustment according to response, is the best way to
decrease the incidence of uterine hyperstimulation.
Next, the parameters we evaluated for efficacy
were the percentage of women delivering vaginally
within 24 hours of induction, total misoprostol dos-
age and induction failure rate. It is encouraging to note
that the percentage of women with intervals from
induction to vaginal delivery within 24 hours was above
90%, when compared with other studies [11,18]. Of
particular interest were the lack of induction failure
and the range of doses from 40 to 1,120 μg below the
maximum cumulative dosage. It was also noted that,
with titrated oral misoprostol dosing, duration of the
active phase was shorter than the usual natural course
for both nullipara and multipara groups [20,21]. In
conclusion, titrated oral misoprostol is a safe and
effective method of labor induction as dosage can be
adjusted according to individual response.
After the encouraging results of this pilot study, in
future, it would be worth comparing titrated oral miso-
prostol with regular 4-hourly high doses of 100 μg to
determine the optimal method of labor induction.
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